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Purpose:  Family  with  sequence  similarity  3, member  B  (FAM3B),  also  known  as  PANcreatic  DERived  factor
(PANDER),  is  an islet-speciﬁc  cytokine  predominantly  expressed  in  both  pancreatic  - and  -cells.  FAM3B
is  known  to induce  apoptosis  in  pancreatic  cells,  and  may  therefore  be able  to  regulate  apoptosis  in
other  cell  types,  including  cancer  cells.  However,  the  role  of  FAM3B  in  carcinogenesis  is unknown.  We
previously  performed  global  gene  screening  using  DNA  microarray  analysis  to identify  crucial  molecules
in  oral  squamous  cell  carcinoma  (OSCC).  The  results  showed  signiﬁcant  down-regulation  of  FAM3B  in
OSCC-derived  cell lines,  as  compared  with  human  normal  oral  keratinocytes  (HNOKs).  The  aim of the
present  study  was  to clarify  the association  between  FAM3B  and  OSCCs.
Results: Expression  proﬁles  of  FAM3B  in  OSCC-derived  cell lines  and  human  primary  OSCCs  were
examined  by real-time  quantitative  reverse  transcriptase-polymerase  chain  reaction  and  Western  blot
analysis.  Signiﬁcantly  decreased  expression  of  FAM3B  mRNA  and  FAM3B  protein  were  observed  in  ﬁve
OSCC-derived  cell  lines,  as  compared  with  HNOKs.  Moreover,  immunohistochemical  analysis  revealed
down-regulated  FAM3B  protein  expression  in  primary  OSCC  samples.  In  order  to  examine  whether
microRNA  (miRNA)  potentially  regulates  FAM3B  expression,  miRNA  microarray  analysis  was  performed
with  OSCC-derived  cell  lines.  miRNA  microarray  data  showed  that  miR-181a,  miR-181b,  miR-200b,  and
miR-200c,  which  can induce  imperfect  base  pairing  with  the  3′-untranslated  region  of FAM3B  mRNA,
were  up-regulated  in all cell  lines  examined.
Conclusions: These  results  indicate  that  decreased  FAM3B  expression  is  able  to promote  OSCC  progression
and  that  certain  miRNAs  may  be correlated  with  the  altered  expression  of  FAM3B.
 Japan© 2012
. Introduction
Oral squamous cell carcinomas (OSCCs), the most common can-
er of the head and neck, account for over 300,000 new cancer
ases worldwide annually [1]. OSCC has been identiﬁed as a major
lobal threat to public health, and its prognosis has not improved
n decades [2–4]. With currently available clinical assessment and
reatment methods, a third of all cases of oral cancer are diagnosed
nly after becoming locally advanced [5,6]. In addition, aggressive
reatment of OSCCs is controversial because it can lead to severe
orbidity and disﬁgurement. As a result, many patients with OSCCs
re either over-treated or untreated, with substantial personal and
ocioeconomic implications.
A  number of etiologic factors have been implicated in the
evelopment of OSCCs, such as the use of tobacco, alcohol, or
∗ Corresponding author. Tel.: +81 43 226 2300; fax: +81 43 226 2300.
E-mail  address: m.shiiba@faculty.chiba-u.jp (M.  Shiiba).
348-8643/$ – see front matter ©  2012 Japanese Stomatological Society. Published by Els
oi:10.1016/S1348-8643(12)00004-3ese Stomatological Society. Published by Elsevier Ltd. All rights reserved.
the presence of incompatible prosthetic materials [6–8]. However,
some patients develop OSCC without risk factors, suggesting that
host susceptibility may  play a role. Molecular alterations in a num-
ber of oncogenes and tumor suppressor genes associated with the
development of OSCC could be important clues for addressing these
issues [7,9]. Comprehensive and exhaustive expression studies of
numerous genes, including functionally unknown genes, are essen-
tial for understanding the complexity and polymorphisms of OSCC
[10–13].
Microarray technologies have been helpful for analyzing
changes in thousands of genes and for identifying signiﬁcant pat-
terns. We  previously reported gene expression proﬁling in OSCC
to identify the genes associated with oral carcinogenesis [14].
Among the genes identiﬁed using microarray analysis, family with
sequence similarity 3, member B (FAM3B) expression was found to
be signiﬁcantly down-regulated.
FAM3B  is a novel 235 amino acid pro-apoptotic cytokine, which
was recently cloned from pancreatic islet cells. FAM3B is expressed
in the islets of Langerhans, small intestine, testis, prostate, and
evier Ltd. All rights reserved.
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ome neurons of the central nervous system [15]. Previous stud-
es have revealed that recombinant FAM3B or overexpression of
AM3B in the pancreatic beta cells induces cell apoptosis in a time-
nd dose-dependent manner [16,17]. The pancreas may  not be the
nly target tissue of FAM3B, which is secreted in response to glu-
ose or other signaling pathways and may  play a metabolic role in
ther tissues [18]. The role of FAM3B in OSCC progression is poorly
nderstood.
Therefore, the aim of this study was to investigate expression
roﬁles of FAM3B in OSCC and to clarify the relationship between
heir expression proﬁles and clinical features.
. Materials and methods
.1.  OSCC-derived cell lines and tissue specimens
HSC-2, HSC-3, HSC-4, and KOSC2, derived from human OSCCs,
ere purchased from the Human Science Research Resources Bank,
saka, Japan. Sa3 was kindly provided by Dr S. Fujita at Wakayama
edical University, Wakayama, Japan. Primary cultured human
ormal oral keratinocytes (HNOKs) were obtained from three
ealthy donors, and were used as normal controls. All cells were
rown in Dulbecco’s modiﬁed Eagle medium (DMEM) (Sigma, St.
ouis, MO,  USA) supplemented with 10% fetal bovine serum (FBS)
Sigma) and 50 units/ml penicillin and streptomycin (Sigma).
.2. Tissue specimens
Primary  OSCCs and patient-matched normal oral epithelial sam-
les were obtained during surgical resection at Chiba University
ospital after all patients provided informed consent, in accor-
ance with the protocol approved by the Institutional Review
oard of Chiba University. Resected tissues were divided into
wo parts, one of which was frozen immediately and stored at
80 ◦C until RNA isolation, and the second of which was  ﬁxed in
0% buffered formaldehyde solution for pathologic diagnosis and
mmunohistochemical analysis. Histopathologic analysis of the tis-
ues was performed according to the World Health Organization
riteria by the Department of Pathology, Chiba University Hospi-
al. Clinicopathological staging was determined according to the
umor-node-metastases classiﬁcation of the International Union
gainst Cancer. All patients had OSCC that was histologically con-
rmed, and tumor samples were examined to ensure that tumor
issue was present in more than 80% of specimens.
.3. RNA extraction and reverse transcription
Total RNA was extracted using Trizol Reagent (Invitrogen, Carls-
ad, CA, USA), according to the manufacturer’s instructions. Quality
f total RNA was determined using Bioanalyzer (Agilent Technolo-
ies, Santa Clara, CA, USA). Extracted RNA samples were stored
eparately at −80 ◦C until use.
.4.  Preparation of cDNA
Total  RNA was isolated from cells and tissues using Trizol
eagent (Invitrogen) and was reverse-transcribed by Ready-to-Go
ou-Prime ﬁrst-strand beads (GE Healthcare, Little Chalfont, UK)
nd Oligo(dT) primer (Hokkaido System Science Co., Ltd., Sapporo,
apan).
.5. mRNA expression analysisReal-time  quantitative reverse transcriptase-polymerase chain
eaction (qRT-PCR) was performed to evaluate the expression level
f FAM3B mRNA in the OSCC-derived cell lines (HSC-2, HSC-3,ernational 9 (2012) 9– 16
HSC-4,  KOSC2, and Sa3) and HNOKs. Primary OSCCs and paired
specimens of normal oral tissues obtained from 65 patients also
were evaluated. qRT-PCR was performed with a single method
using a LightCycler® 480 PCR system (Roche Diagnostics GmbH,
Mannheim, Germany) and LightCycler® 480 Probes Master (Roche
Diagnostics GmbH).
Primers  and Taqman probes were designed using Probe
Finder in the Universal Probe Library (UPL) Assay Design
Center (Roche Applied Science, Mannheim, Germany). The
nucleotide sequences of gene-speciﬁc primers for qRT-PCR ampli-
ﬁcation and number of Universal probes were as follows:
FAM3B, forward, 5′-TGTCGTGTCCACATGTTT-3′; and reverse, 5′-
GAAGACCACGAACACCAC-3′. The Universal Probe used was  #57.
PCR using the LightCycler apparatus was  carried out in a reaction
mixture with a ﬁnal volume of 20 l, containing 5 l of template
cDNA, 2 l of Master Mix, 1 l of Universal Probe and l M primers,
according to the manufacturer’s instructions. Ampliﬁcation was
initiated by a 10 min  pre-incubation at 95 ◦C, followed by 45 cycles
of 10 s at 95 ◦C for template denaturation and 30 s at 55 ◦C for
primer annealing/extension, and a cooling step for 30 s at 40 ◦C.
The transcript amounts for FAM3B were estimated using standard
curves, and were normalized against glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (forward, 5′-CATCTCTGCCCCCTCTGCTGA-
3′, and reverse, 5′-GGATGACCTTGCCCACAGCCT-3′; Universal Probe
#60) transcripts determined in corresponding samples.
2.6.  Protein extraction
OSCC-derived cell lines were washed twice with cold
phosphate-buffered saline (PBS) and centrifuged brieﬂy. Cell pel-
lets were incubated at 4 ◦C for 30 min  in lysis buffer (7 M urea,
2 M thiourea, 4% (w/v) CHAPS, and 10 mM Tris, pH 7.4) con-
taining proteinase inhibitor cocktail (Roche Diagnostics GmbH).
Protein concentrations were measured using a BCA Protein Assay
Kit (Thermo Fisher Scientiﬁc, Waltham, MA,  USA).
2.7. Western blot analysis
Protein  extracts (30 g) were separated by sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS–PAGE) on 4–12% gels,
transferred to nitrocellulose membranes (Invitrogen), and blocked
for 1 h at room temperature in Blocking One (Nacalai Tesque,
Tokyo, Japan). Membranes were incubated with rabbit anti-FAM3B
antibody (Proteintech, Chicago, IL, USA) for 4 h at room tempera-
ture and mouse anti--actin antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) for 1 h at room temperature. Membranes were
washed with 0.1% Tween-20 in Tris-buffered saline, incubated
with secondary antibodies and coupled to horseradish peroxidase-
conjugated anti-rabbit or anti-mouse IgG for 1 h at room tempera-
ture. Proteins were detected using SuperSignal Chemiluminescent
substrate (Thermo Fisher Scientiﬁc). Finally, immunoblotting
results were visualized by exposing the membrane to a cooled
CCD camera system (ATTO, Tokyo, Japan). Signal intensities were
quantitated using the CS Analyzer version 3.0 (ATTO).
2.8.  Immunohistochemical analysis
Immunohistochemical analysis was performed on 4-m
sections of parafﬁn-embedded specimens using anti-FAM3B
polyclonal antibody (Proteintech). Brieﬂy, after deparafﬁnization
and hydration, endogenous peroxidase activity was quenched by
30-min incubation in a mixture of 0.3% hydrogen peroxide solution
in 100% methanol; sections were blocked for 2 h at room temper-
ature with 1.5% blocking serum (Santa Cruz Biotechnology) in PBS
before reacting with rabbit anti-FAM3B antibody (1:500 dilution)
at 4 ◦C in a moist chamber overnight. Upon incubation with the
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Fig. 1. Family with sequence similarity 3, member B (FAM3B) mRNA expression
in  oral squamous cell carcinoma (OSCC)-derived cell lines. FAM3B mRNA levels
were  analyzed in OSCC-derived cells and human normal oral keratinocytes (HNOKs)
by real-time quantitative reverse transcriptase-polymerase chain reaction analysis.
Signiﬁcant down-regulation of FAM3B mRNA was  observed in the ﬁve OSCC-derived
cell  lines, as compared with HNOKs (*p < 0.05; Mann–Whitney U-test). Data are
expressed as means ± SEM of triplicate experiments.
Fig. 2. Family with sequence similarity 3, member B (FAM3B) protein expression in
oral squamous cell carcinoma (OSCC)-derived cell lines. FAM3B protein expression
in  OSCC-derived cell lines was analyzed with Western blot analysis. FAM3B and
-actin protein were detected by rabbit anti-FAM3B antibody and mouse anti--
actin  antibody, respectively (A). FAM3B protein signals were normalized against -
actin expression, and FAM3B expression levels of OSCC-derived cell lines are shown
as relative values vs. human normal oral keratinocytes (HNOKs) (B). The results
showed  FAM3B protein expression is signiﬁcantly diminished in OSCC-derived cell
lines when compared with HNOKs.ernational 9 (2012) 9– 16 11
primary antibody, specimens were washed three times in PBS and
treated with Histoﬁne Simplestain Max-PO (G) (Nichirei, Tokyo,
Japan), followed by color development in 3,3′-diaminobenzidine
tetrahydrochloride (DAKO, Carpinteria, CA, USA). Finally, slides
were counterstained lightly with hematoxylin, dehydrated with
ethanol, cleaned with xylene, and mounted. Some nonspeciﬁc
antibody binding was observed. To investigate the nonspeciﬁc
binding of the FAM3B antibody, an immunizing peptide block-
ing experiment was performed. As a negative control, triplicate
sections were immunostained without exposure to primary anti-
bodies, thus conﬁrming staining speciﬁcity. To quantify the state
of FAM3B protein expression in these components, we used the
immunohistochemical (IHC) score system described previously
[19]. The intensity of the FAM3B immunoreaction was  scored as
follows: 1+, weak; 2+, moderate; and 3+, intense. Cell number
and staining intensity were then multiplied to produce a FAM3B
IHC score. Cases with a FAM3B IHC score of less than 93.0 (lowest
score for normal tissue) were deﬁned as FAM3B negative. Two
independent pathologists, neither of whom had any knowledge of
patient clinical status, made these determinations.
2.9. MicroRNA microarray analysis
MicroRNAs (miRNAs) were puriﬁed from RNA samples
extracted from HSC-2, HSC-3, and Sa3 cells using PureLinkTM (Invit-
rogen). miRNAs were subjected to poly-A tailing reactions, and
samples were incubated with 28.5 l of 2× enhanced hybridiza-
tion buffer at 65 ◦C for 10 min  and were then loaded onto NCode
Human miRNA Microarray V3 (Invitrogen). Arrays were mounted
with the Maui Mixer SL and hybridized overnight at 52 ◦C with con-
stant mixing. The following day, arrays were washed and scanned
using a GenePix 4000B microarray scanner. Arrayed images were
annotated and analyzed using GenePix software (Invitrogen) and
the GenePix Array List (Invitrogen) ﬁle containing the array list for
human samples.2.10.  Analysis of predicted target gene
In order to identify miRNAs that can directly regulate FAM3B
mRNA, miRNA array data were analyzed using publicly available
Fig. 3. Expression proﬁle of family with sequence similarity 3, member B (FAM3B)
mRNA  in primary oral squamous cell carcinoma (OSCC) samples. Down-regulated
expression  of FAM3B mRNA was validated against primary OSCC samples using real-
time quantitative reverse transcriptase-polymerase chain reaction analysis. Relative
mRNA expression levels in normal oral tissues and primary OSCCs ranged from 0.049
to 1.503 (median, 0.262) and 0.017 to 0.656 (median, 0.028), respectively (p = 0.0047;
paired t-test).
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Fig. 4. Immunohistochemical (IHC) analysis of family with sequence similarity 3, member B (FAM3B) protein expression in primary oral squamous cell carcinoma (OSCC)
samples. Representative results of IHC analysis for FAM3B in normal oral tissue (A, B) and primary OSCC (C, D). Original magniﬁcation: ×100 (A, C) and ×400 (B, D). Positive
immunoreactions for FAM3B in normal oral tissue were detected in cytoplasm. Primary OSCC tissues exhibited faint FAM3B protein expression. FAM3B IHC scores are shown
(E).  FAM3B IHC scores for OSCCs and normal oral tissues range from 24.0 to 162.0 (median, 60.0) and 93.0 to 252.0 (median, 152.5), respectively. FAM3B protein expression
levels in OSCCs were signiﬁcantly lower than those in normal oral tissues (p < 0.001; Mann–Whitney U-test).
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lgorithms. The databases used in the present study were
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http://www.microrna.org/microrna).
. Results
.1. Analysis of FAM3B mRNA and FAM3B protein expression in
SCC-derived  cell lines
We  examined FAM3B mRNA and protein expression in ﬁve
SCC-derived cell lines (HSC-2, HSC-3, HSC-4, KOSC2, and Sa3)
nd HNOKs using real-time qRT-PCR and Western blot analyses.
igniﬁcant down-regulation of FAM3B mRNA was observed in all
SCC cell lines when compared with HNOKs (Fig. 1) (*p < 0.05).
ig. 2 shows representative results of Western blot analysis. The
olecular weight of FAM3B was 26.0 kDa. The values obtained from
ensitometric analysis of FAM3B protein were normalized against
-actin levels and were then expressed as relative values. A sig-
iﬁcant decrease in FAM3B protein expression was  observed in all
SCC cell lines when compared with HNOKs.
.2. Analysis of FAM3B mRNA and FAM3B protein expression in
rimary  OSCCs
We  evaluated FAM3B mRNA expression in primary OSCCs. Real-
ime qRT-PCR analysis showed that FAM3B mRNA expression was
own-regulated in 46 (71%) of 65 primary OSCCs when compared
ith matched normal oral tissues. Relative mRNA expression lev-
ls in the normal oral tissues and primary OSCCs ranged from
Table 1
Correlation between family with sequence similarity 3,
logical factors.
Clinical class ifi cation
Total 
Age at surgery (years)
<60 16 
≥60, <70 10
≥70 24 
Gend er
Male 31 
Female 19 
T-primary tumor
T1 or T2 34 
T3 or T4 16 
Sta ge
I or  II 25 
III or IV 25 
Histop athologic type
Well 31 
Moderate ly 15 
Poorly 4 
Total 50 
¶FAM3B expression was categorized by the relative valu
score). OSCC cases were divided into FAM3B-positive (IH
*Statistical signiﬁcance (p < 0.05) was  determined by Chiernational 9 (2012) 9– 16 13
0.049  to 1.503 (median, 0.262) and 0.017 to 0.656 (median, 0.028),
respectively (Fig. 3) (p = 0.0047). In addition to the FAM3B mRNA
expression data in primary OSCCs, FAM3B protein expression in
primary OSCC was investigated by immunohistochemical analysis.
The data revealed signiﬁcantly lower FAM3B expression in OSCC
samples than in normal tissues (Fig. 4A–D). The FAM3B IHC scores
for normal oral tissues and primary OSCCs ranged from 93.0 to
252.0 (median, 152.5) and 24.0 to 162.0 (median, 60.0), respec-
tively, and there was  a statistically signiﬁcant difference between
FAM3B expression in OSCCs and in normal tissues (Fig. 4E). The
correlation between clinicopathological factors of patients with
OSCC and the status of FAM3B protein expression was  analyzed
by IHC (Table 1), and FAM3B expression was categorized based
on relative values (T/N ratio of IHC score). We set 0.5 as a cut
off value for T/N ratio of IHC score, and OSCC cases were divided
into FAM3B-positive (IHC ratio > 0.5) and FAM3B-negative (IHC
ratio < 0.5). FAM3B expression was positive in 59% of T1 or T2
tumors, 25% of T3 or T4 tumors. There was  a statistically signiﬁ-
cant relationship between FAM3B expression and primary tumor
size (p = 0.026) (Table 1), with higher FAM3B expression in smaller
tumors (T1 or T2) when compared with larger tumors (T3 or T4).
Furthermore, FAM3B expression was signiﬁcantly lower in the
advanced stage group (stage III or IV) than in the early stage group
(stage I or II) (p = 0.005).3.3. MicroRNA array analysis
In  order to identify miRNAs that potentially regulate FAM3B
mRNA expression, microRNA array analysis was performed.
 member B(FAM3B)expression and clinicopatho-
Results of immunostain ing
¶
Number of patients (%)
FAM3B (-) FAM3B (+) p-value
8 (50%) 8 (50%)
0.610
6 (60%) 4 (40%)
10 (42%) 14 (58%)
16 (52%) 15 (48%)
0.944
10 (53%) 9 (47%)
14 (41%) 20 (59%)
0.026*
12 (75%) 4  (25%)
8 (32%) 17 (68%)
0.005*
18 (72%) 7 (28%)
15 (48%) 16 (52%)
0.7589 (60%) 6 (40%)
2 (50%) 2 (50%)
24 (40) 26 (60)
e of immunohistochemical score (T/N ratio of IHC
C ratio > 0.5) and FAM3B-negative (IHC ratio < 0.5).
-square test.
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cig. 5. Predicted target genes of microRNAs (miRNAs). Predicted target genes of m
ublicly available algorithms (TargetScan and microRNA.org). The results suggested
igniﬁcantly up-regulated miRNAs that can suppress FAM3B
xpression through base pairing with the 3′-untranslated region
UTR) of FAM3B mRNA were searched for, and the database
dentiﬁed miR-181a, miR-181b, miR-200b, and miR-200c as can-
idate miRNAs (Fig. 5). Expression levels of miR-181a, miR-181b,
iR-200b, and miR-200c were higher in all OSCC-derived cell lines
xamined, as compared to levels in HNOKs (Fig. 6). Analysis of
redicted target genes showed that miR-181a, miR-181b, miR-
00b, and miR-200c potentially interact with FAM3B mRNA, thus
uggesting that FAM3B expression is regulated by these miRNAs.
.  Discussion
FAM3B is a secreted cytokine expressed at high levels in the
slets of Langerhans of the endocrine pancreas [16,20] that induces
- and -cell apoptosis [18]. Dysregulation of apoptosis is a crucial
vent frequently observed in various tumor cells. Thus, it is rea-
onable to believe that up-regulated or down-regulated apoptotic
ctivity induced by FAM3B is present in other cell types, includ-
ng human carcinomas. However, few reports on the association
etween FAMB3 and human tumors have been published.
We  previously reported gene expression proﬁling of oral car-
inogenesis in OSCC using microarray analysis. The data suggested1a, miR-181b, miR-200b, and miR-200c are shown. Analysis was performed using
FAM3B mRNA is the target gene of these 4 miRNAs.
FAM3B  is one of the most signiﬁcantly down-regulated genes in
OSCC-derived cell lines [21]. Thus, we  speculated that FAM3B is
associated with OSCC, probably through dysregulated apoptotic
activity. To clarify the relationship between FAM3B and OSCC, the
expression proﬁles of FAM3B mRNA and FAM3B protein were inves-
tigated in OSCC-derived cell lines and primary OSCC samples. The
data showed that signiﬁcant down-regulation of FAM3B mRNA
and FAM3B protein was present in OSCC-derived cell lines and
primary OSCC samples. These results are consistent with our previ-
ously reported DNA microarray data [21] and strongly suggest that
FAM3B plays a crucial role in OSCC.
FAM3B is capable of inducing apoptosis in pancreatic islet
-cell and neuroblastoma cells [16,22]. Burkhardt et al. reported
that FAM3B-induced down-regulation of cyclin-dependent kinase
inhibitor 1A (CDKN1A) expression and coupled with induced
Caspase3-activation may  serve a central role in islet cell death
[23]. Thus, decreased expression of FAM3B may  be associated with
tumorigenesis in OSCC and suppression of apoptosis could play a
crucial role in the process [24]. The role of FAM3B in normal epithe-
lium remains unknown. Based on the present data, we speculate
that FAM3B secreted by oral epithelial cells under normal condi-
tions could regulate ordinary cell metabolism, probably through
apoptotic activity, and that transformation of the epithelial cells
M. Shiiba et al. / Oral Science International 9 (2012) 9– 16 15
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Hig. 6. Expression proﬁles of microRNAs (miRNAs) in oral squamous cell carcinoma 
SCC.  The expression values for miR-181a, miR-181b, miR-200b, and miR-200c were g
HNOKs).
ay  induce the loss of various crucial cellular functions, including
AM3B secretion, which leads to disordered cell proliferation. Fur-
her studies are necessary to elucidate the molecular mechanisms
esponsible for FAM3B-related tumorigenesis.
Correlations between the clinicopathological characteristics of
atients with OSCC and the status of FAM3B protein expression
sing the IHC scoring system are shown in Table 1. Among the clin-
cal classiﬁcations, size of primary tumor and stage classiﬁcation
ere correlated with the expression proﬁle of FAM3B. Signiﬁ-
antly down-regulated expression of FAM3B was  observed in larger
umors (T1 or T2) and in advanced cases (Stage III or IV). The results
uggest that down-regulated expression of FAM3B is closely associ-
ted with tumor development and that FAM3B is a useful biomarker
f OSCC.
miRNAs are endogenous, small, noncoding RNAs of ∼23
ucleotides that are involved in essential biological activities.
hese activities are performed by regulating target gene expression
hrough imperfect base pairing with the 3′-UTR of target mRNAs
f protein-encoding genes, leading to the cleavage of homologous
RNA or translational inhibition. Recent studies have revealed dif-
erential expression proﬁles of miRNAs in various types of cancers,
ncluding oral cancer, suggesting that certain miRNAs play crucial
oles in tumorigenesis [25,26].
In oral cancer, crucial miRNAs for proliferation, metastasis and
hemotherapy resistance have been reported in various studies
27]. Although these investigations strongly suggest that some miR-
As have crucial roles in OSCC, little is known about their functions.
n the present study, global gene screening of OSCC-derived cell
ines with miRNA microarray analysis revealed that the expres-
ion levels of miR-181a, miR-181b, miR-200b, and miR-200c were
reater in 3 OSCC-derived cell lines (HSC-2, HSC-3, and Sa3) than in
NOKs. As some target gene prediction algorithms have suggested)-derived cell lines. MiRNA microarray was performed to identify crucial miRNAs in
 in HSC-2, HSC-3, and Sa3 cells, as compared with human normal oral keratinocytes
that  these miRNAs regulate FAM3B mRNA  expression by pairing
with the 3′-UTR of FAM3B mRNA, they may  induce down-regulation
of FAMB3 expression. The expression levels of FAM3B protein were
comparable among OSCC-derived cell lines examined (Fig. 2). Thus,
we speculate that the decreased expression of FAM3B is induced by
miR-181a, miR-181b, miR-200b, and miR-200c in OSCC-derived cell
lines. The present data indicate that FAM3B expression is associ-
ated with OSCC, and its reduced expression may  be regulated by
certain miRNAs.
Cervigne et al. reported that miR-181b was consistently ele-
vated and associated with increases in lesion severity during OSCC
progression [28]. In addition, a recent study has suggested that
over-expression of miR-181 is correlated with lymph-node metas-
tasis, vascular invasion and poor survival in OSCC cases [29]. Yu
et al. reported up-regulation of miR-200b in an animal model
of OSCC [30], and over-expression of miR-200b has been con-
ﬁrmed in head and neck cancer cell lines [31]. These studies
strongly suggest that miR-181 and miR-200 play a crucial role
in oral carcinogenesis. However, the functions of these miRNAs
remain unknown. Recently, certain mRNAs and miRNAs have been
detected in saliva and can be used as biomarkers in oral cancer [32].
However, FAM3B, miR-181a, miR-181b, miR-200b, and miR-200c
have not yet been established as biomarkers in oral cancer, although
further investigation may  identify clinical applications for these
genes.
In conclusion, the present results revealed that FAM3B is fre-
quently down-regulated in OSCC and is closely associated with the
progression of primary OSCC. In addition, miR-181a, miR-181b, miR-
200b, and miR-200c may  be responsible for the decrease in FAM3B
expression. The present study strongly suggests that FAM3B plays
an important role in OSCC and that it may be a useful biomarker of
progression in primary OSCC.
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